Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Newer-Generation DES, Really Nothing to Special?

  • Hyun Sung Joh (Department of Internal Medicine and Cardiovascular Center, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine)
  • Received : 2024.05.02
  • Accepted : 2024.05.07
  • Published : 2024.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9. https://doi.org/10.1016/j.jcin.2008.11.015
  2. Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol 2013;61:536-44. https://doi.org/10.1016/j.jacc.2012.11.015
  3. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8. https://doi.org/10.1016/S0735-1097(03)00119-0
  4. Kobayashi T, Sotomi Y, Suzuki S, et al. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. Cardiovasc Interv Ther 2020;35:250-8. https://doi.org/10.1007/s12928-019-00613-w
  5. Taglieri N, Bruno AG, Ghetti G, et al. Target lesion failure with current drug-eluting stents: evidence from a comprehensive network meta-analysis. JACC Cardiovasc Interv 2020;13:2868-78. https://doi.org/10.1016/j.jcin.2020.09.014
  6. Iglesias JF, Roffi M, Losdat S, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet 2023;402:1979-90. https://doi.org/10.1016/S0140-6736(23)02197-9
  7. Park S, Rha SW, Choi BG, et al. Efficacy and safety of sirolimus-eluting stent with biodegradable polymer Ultimaster™ in unselected Korean population: a multicenter, prospective, observational study from Korean Multicenter Ultimaster Registry. Korean Circ J 2024;54:339-50. https://doi.org/10.4070/kcj.2024.0023
  8. Yoon CH, Jang J, Hur SH, et al. Osstem Cardiotec Centum stent versus Xience Alpine stent for de novo coronary artery lesion: a multicenter, randomized, parallel-designed, single blind test. Korean Circ J 2022;52:354-64. https://doi.org/10.4070/kcj.2021.0198
  9. Kuramitsu S, Sonoda S, Ando K, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther 2021;36:158-68. https://doi.org/10.1007/s12928-021-00754-x
  10. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation 2016;133:650-60. https://doi.org/10.1161/CIRCULATIONAHA.115.019071
  11. Coughlan JJ, Maeng M, Raber L, et al. Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Rev Esp Cardiol (Engl Ed) 2022;75:894-902. https://doi.org/10.1016/j.rec.2022.02.003